転移性骨疾患の世界市場レポート 2025年

転移性骨疾患市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.8％で274億9,000万米ドルに成長します。予測期間の成長は、高齢者人口の増加、新規放射性医薬品開発への注目の高まり、償還政策、最先端治療の創出、効果的な疼痛管理治療への需要の高まり、転移性骨疾患に対する認知度の高まりなどに起因すると考えられます。予測期間における主な動向としては、診断の技術開発、診断技術の向上、治療アプローチの新規性、人工知能や機械学習アルゴリズム、骨の健康管理の技術開発などが挙げられます。

骨がんの有病率の増加は、転移性骨疾患市場の成長を促進すると予想されます。骨の細胞に発生する悪性腫瘍である骨がんは、遺伝的要因、放射線被曝、特定の化学物質への暴露などの環境要因によって引き起こされます。骨がんは、原発腫瘍のがん細胞が血流やリンパ系を介して広がり、他の骨に新たな腫瘍を形成するため、転移性骨疾患につながる可能性があります。例えば、米国を拠点とする非営利団体である米国がん協会は、2023年に骨および関節がんの新規症例を3,970例報告したが、これは2022年に報告された3,910例より増加しています。したがって、骨がんの有病率の増加が転移性骨疾患市場の成長を牽引しています。

転移性骨疾患市場の主要企業は、治療成果を改善するために標的治療を開発しています。これらの標的療法は、がん細胞を正確に標的とし、健康な細胞へのダメージを最小限に抑え、個々の患者の分子特性に基づいた個別化治療アプローチを提供することで、転移性骨疾患に貢献しています。例えば、2022年3月、スイスに本社を置く製薬会社ノバルティスAGは、固形がんおよび多発性骨髄腫の骨転移患者における骨格関連事象の予防を適応症として承認されたビスフォスフォネート系薬剤であるゾメタ（ゾレドロン酸）を発表しました。これらの進歩は、転移性骨疾患を持つ患者の治療成績と生活の質を改善することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界転移性骨疾患PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の転移性骨疾患市場：成長率分析
• 世界の転移性骨疾患市場の実績：規模と成長, 2019-2024
• 世界の転移性骨疾患市場の予測：規模と成長, 2024-2029, 2034F
• 世界転移性骨疾患総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の転移性骨疾患市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬
• 放射線治療
• 外科的介入
• 腫瘍アブレーション療法
• 世界の転移性骨疾患市場起源別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胸
• 肺
• 甲状腺
• 腎臓
• 前立腺
• その他の起源
• 世界の転移性骨疾患市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• 世界の転移性骨疾患市場、医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビスホスホネート
• デノスマブ
• 化学療法薬
• ホルモン療法
• 標的療法
• 放射線治療
• 世界の転移性骨疾患市場放射線治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線療法
• 内部放射線療法
• 世界の転移性骨疾患市場、外科的介入の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 骨安定化手術
• 骨切除手術
• 脊椎減圧手術
• 世界の転移性骨疾患市場腫瘍アブレーション療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高周波アブレーション
• 凍結療法
• マイクロ波アブレーション

第7章 地域別・国別分析

• 世界の転移性骨疾患市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の転移性骨疾患市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 転移性骨疾患市場：競合情勢
• 転移性骨疾患市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• GSK plc
• Takeda Pharmaceutical Company Limited
• Medtronic plc
• Eli Lilly and Company
• Amgen Inc.
• Boston Scientific Corporation
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Jazz Pharmaceuticals Inc.
• Exelixis Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 転移性骨疾患市場2029：新たな機会を提供する国
• 転移性骨疾患市場2029：新たな機会を提供するセグメント
• 転移性骨疾患市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Metastatic bone disease refers to the condition where cancer cells spread from their original (primary) site to the bones, causing bone weakening and symptoms such as pain, fractures, spinal cord compression, and hypercalcemia. This indicates that the cancer has progressed and is more challenging to treat.

The main treatments for metastatic bone disease include medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication involves pharmaceutical drugs used to manage symptoms, slow disease progression, or address the underlying causes of bone metastases. These treatments are applicable to cancers originating from the breast, lung, thyroid, kidney, prostate, and other sites. The various end-users of these treatments include hospitals, specialty clinics, and ambulatory surgical centers.

The metastatic bone disease market research report is one of a series of new reports from The Business Research Company that provides metastatic bone disease market statistics, including the metastatic bone disease industry global market size, regional shares, competitors with metastatic bone disease market share, detailed metastatic bone disease market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic bone disease industry. These metastatic bone disease market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic bone disease market size has grown rapidly in recent years. It will grow from $17.14 billion in 2024 to $18.88 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to an increased aging population, increased cancer awareness programs, growth in the demand for effective pain management therapies, high investment in drug discovery and development, and adoption of unhealthy lifestyles.

The metastatic bone disease market size is expected to see strong growth in the next few years. It will grow to $27.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to the increasing geriatric population, increasing focus on developing novel radiopharmaceutical drugs, reimbursement policies, creation of cutting-edge treatment, growing demand for effective pain management therapies, and rising awareness about metastatic bone disease. Major trends in the forecast period include technological developments in diagnostics, improved diagnostic techniques, novelties in therapeutic approaches, artificial intelligence and machine learning algorithms, and technological developments in the management of bone health.

The increasing prevalence of bone cancer is expected to propel the growth of the metastatic bone disease market. Bone cancer, a malignant tumor originating in the cells of the bone, is driven by genetic factors, radiation exposure, and environmental factors such as exposure to certain chemicals. Bone cancer can lead to metastatic bone disease as cancer cells from the primary tumor spread through the bloodstream or lymphatic system, forming new tumors in other bones. For instance, in 2023, the American Cancer Society, a US-based non-profit organization, reported 3,970 new cases of bone and joint cancer, an increase from the 3,910 cases reported in 2022. Therefore, the increasing prevalence of bone cancer is driving the growth of the metastatic bone disease market.

Major companies in the metastatic bone disease market are developing targeted therapies to improve treatment outcomes. These targeted therapies help in metastatic bone disease by precisely targeting cancer cells, minimizing damage to healthy cells, and offering a personalized treatment approach based on the individual patient's molecular characteristics. For example, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, introduced Zometa (zoledronic acid), a bisphosphonate medication approved for the prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma. These advancements aim to improve treatment outcomes and quality of life for patients with metastatic bone disease.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix's therapeutic pipeline, strengthening its position in radiopharmaceutical innovation and widening its focus on oncology and rare diseases. Through this deal, Telix intends to accelerate the development and delivery of treatments for bone metastases, aiming to provide significant benefits to affected patients. QSAM Biosciences Inc. is a US-based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Major companies operating in the metastatic bone disease market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Eli Lilly and Company, Amgen Inc., Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Jazz Pharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Mylan N.V., Novocure GmbH, Galapagos NV, Telix Pharmaceuticals Limited

North America was the largest region in the metastatic bone disease market in 2024. The regions covered in the metastatic bone disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic bone disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The metastatic bone disease market consists of revenues earned by entities by providing services such as chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic bone disease market includes sales of intramedullary rods, plates and screws, prosthetic devices, spinal instrumentation, and radiation therapy accessories. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Bone Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic bone disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic bone disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic bone disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medication; Radiation Therapy; Surgical Intervention; Tumor Ablation Therapy
• 2) By Origin: Breast; Lung; Thyroid; Kidney; Prostate; Other Origins
• 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Medication: Bisphosphonates; Denosumab; Chemotherapy Drugs; Hormonal Therapies; Targeted Therapies; Radiation Therapy
• 2) By Radiation Therapy: External Beam Radiation Therapy; Internal Radiation Therapy
• 3) By Surgical Intervention: Bone Stabilization Surgery; Bone Resection Surgery; Spinal Decompression Surgery
• 4) By Tumor Ablation Therapy: Radiofrequency Ablation; Cryoablation; Microwave Ablation
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Bone Disease Market Characteristics

3. Metastatic Bone Disease Market Trends And Strategies

4. Metastatic Bone Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Metastatic Bone Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic Bone Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic Bone Disease Market Growth Rate Analysis
• 5.4. Global Metastatic Bone Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic Bone Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic Bone Disease Total Addressable Market (TAM)

6. Metastatic Bone Disease Market Segmentation

• 6.1. Global Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Radiation Therapy
• Surgical Intervention
• Tumor Ablation Therapy
• 6.2. Global Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast
• Lung
• Thyroid
• Kidney
• Prostate
• Other Origins
• 6.3. Global Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• 6.4. Global Metastatic Bone Disease Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Denosumab
• Chemotherapy Drugs
• Hormonal Therapies
• Targeted Therapies
• Radiation Therapy
• 6.5. Global Metastatic Bone Disease Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Internal Radiation Therapy
• 6.6. Global Metastatic Bone Disease Market, Sub-Segmentation Of Surgical Intervention, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bone Stabilization Surgery
• Bone Resection Surgery
• Spinal Decompression Surgery
• 6.7. Global Metastatic Bone Disease Market, Sub-Segmentation Of Tumor Ablation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiofrequency Ablation
• Cryoablation
• Microwave Ablation

7. Metastatic Bone Disease Market Regional And Country Analysis

• 7.1. Global Metastatic Bone Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic Bone Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Bone Disease Market

• 8.1. Asia-Pacific Metastatic Bone Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Bone Disease Market

• 9.1. China Metastatic Bone Disease Market Overview
• 9.2. China Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Bone Disease Market

• 10.1. India Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Bone Disease Market

• 11.1. Japan Metastatic Bone Disease Market Overview
• 11.2. Japan Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Bone Disease Market

• 12.1. Australia Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Bone Disease Market

• 13.1. Indonesia Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Bone Disease Market

• 14.1. South Korea Metastatic Bone Disease Market Overview
• 14.2. South Korea Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Bone Disease Market

• 15.1. Western Europe Metastatic Bone Disease Market Overview
• 15.2. Western Europe Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Bone Disease Market

• 16.1. UK Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Bone Disease Market

• 17.1. Germany Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Bone Disease Market

• 18.1. France Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Bone Disease Market

• 19.1. Italy Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Bone Disease Market

• 20.1. Spain Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Bone Disease Market

• 21.1. Eastern Europe Metastatic Bone Disease Market Overview
• 21.2. Eastern Europe Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Bone Disease Market

• 22.1. Russia Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Bone Disease Market

• 23.1. North America Metastatic Bone Disease Market Overview
• 23.2. North America Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Bone Disease Market

• 24.1. USA Metastatic Bone Disease Market Overview
• 24.2. USA Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Bone Disease Market

• 25.1. Canada Metastatic Bone Disease Market Overview
• 25.2. Canada Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Bone Disease Market

• 26.1. South America Metastatic Bone Disease Market Overview
• 26.2. South America Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Bone Disease Market

• 27.1. Brazil Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Bone Disease Market

• 28.1. Middle East Metastatic Bone Disease Market Overview
• 28.2. Middle East Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Bone Disease Market

• 29.1. Africa Metastatic Bone Disease Market Overview
• 29.2. Africa Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Bone Disease Market Competitive Landscape And Company Profiles

• 30.1. Metastatic Bone Disease Market Competitive Landscape
• 30.2. Metastatic Bone Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Bone Disease Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Novartis AG
• 31.5. GSK plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Medtronic plc
• 31.8. Eli Lilly and Company
• 31.9. Amgen Inc.
• 31.10. Boston Scientific Corporation
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Astellas Pharma Inc.
• 31.13. Daiichi Sankyo Company Limited
• 31.14. Jazz Pharmaceuticals Inc.
• 31.15. Exelixis Inc.

32. Global Metastatic Bone Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Bone Disease Market

34. Recent Developments In The Metastatic Bone Disease Market

35. Metastatic Bone Disease Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic Bone Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic Bone Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic Bone Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer